Mometasone (topical): Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "{{DrugProjectFormSinglePage |authorTag={{AV}} <!--Overview--> |genericName=mometasone furoate (topical) |aOrAn= a |drugClass=anti-inflammatory |indication= |has...")
 
m (Protected "Mometasone (topical)": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(4 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag={{AV}}
|authorTag={{AV}}<!--Overview-->
 
|genericName=mometasone furoate (topical)
 
|aOrAn=an
<!--Overview-->
|drugClass=[[anti-inflammatory]]
 
|indicationType=treatment
|genericName=mometasone furoate (topical)  
|indication=[[inflammatory]] and [[pruritic]] manifestations of [[corticosteroid]]-responsive [[dermatoses]]
 
|adverseReactions=[[abdominal pain]], [[candidiasis]], [[indigestion]], [[nausea]], [[backache]], [[musculoskeletal pain]], [[myalgia]], [[headache]], [[dysmenorrhea]], [[allergic rhinitis]], [[epistaxis]], [[pharyngitis]], [[upper respiratory infection]].
 
 
|aOrAn=
 
a
 
|drugClass=anti-inflammatory
 
 
 
|indication=
 
 
 
|hasBlackBoxWarning=
 
 
 
|adverseReactions=






<!--Black Box Warning-->
<!--Black Box Warning-->
 
|blackBoxWarningTitle=Title
|blackBoxWarningTitle=
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>


* Content
* Content
Line 42: Line 19:


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=*Mometasone furoate topical solution USP, 0.1%, is a medium potency [[corticosteroid]] indicated for the relief of the inflammatory and [[pruritic]] manifestations of [[corticosteroid]]-responsive [[dermatoses]]. Since safety and efficacy of mometasone furoate topical solution USP, 0.1% have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended.  
|fdaLIADAdult=
 
*Mometasone furoate topical solution USP, 0.1%, is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Since safety and efficacy of mometasone furoate topical solution USP, 0.1% have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended.  
====Dosage====
====Dosage====


*Apply a few drops of mometasone furoate topical solution USP, 0.1% to the affected skin areas once daily and massage lightly until it disappears. For the most effective and economical use, hold the nozzle of the bottle very close to the affected areas and gently squeeze. Since safety and efficacy of mometasone furoate topical solution USP, 0.1% have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended.
*Apply a few drops of mometasone furoate topical solution USP, 0.1% to the affected skin areas once daily and massage lightly until it disappears. For the most effective and economical use, hold the nozzle of the bottle very close to the affected areas and gently squeeze. Since safety and efficacy of mometasone furoate topical solution USP, 0.1% have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended.


*As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
*As with other [[corticosteroids]], therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.


*Mometasone furoate topical solution USP, 0.1% should not be used with occlusive dressings unless directed by a physician. Mometasone furoate topical solution USP, 0.1% should not be applied in the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.
*Mometasone furoate topical solution USP, 0.1% should not be used with occlusive dressings unless directed by a physician. Mometasone furoate topical solution USP, 0.1% should not be applied in the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.
Line 56: Line 30:


<!--Guideline-Supported Use (Adult)-->
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultGuideSupport=
 
 
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultNoGuideSupport=
 
 
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
|fdaLIADPed=
 
 
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.


<!--Off-Label Use and Dosage (Pediatric)-->
<!--Off-Label Use and Dosage (Pediatric)-->


<!--Guideline-Supported Use (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedGuideSupport=
 
 
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedNoGuideSupport=
 
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
 
|contraindications=* Mometasone furoate topical solution USP, 0.1% is contraindicated in those patients with a history of [[hypersensitivity]] to any of the components in the preparation.
|contraindications=
 
* Mometasone furoate topical solution USP, 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.


<!--Warnings-->
<!--Warnings-->
|warnings=====Precautions====


|warnings=
* Systemic absorption of topical [[corticosteroids]] can produce reversible [[hypothalamic-pituitary-adrenal (HPA) axis suppression]] with the potential for [[glucocorticosteroid]] insufficiency after withdrawal of treatment. Manifestations of [[Cushing's syndrome]], [[hyperglycemia]], and [[glucosuria]] can also be produced in some patients by systemic absorption of topical [[corticosteroids]] while on treatment. Patients applying a topical [[steroid]] to a large surface area or areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the [[ACTH stimulation]], A.M. plasma [[cortisol]], and urinary free [[cortisol]] tests.
 
* Description
 
====Precautions====
 
* Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests.


In a study evaluating the effects of mometasone furoate lotion on the hypothalamic-pituitary-adrenal (HPA) axis, 15 mL were applied without occlusion twice daily (30 mL per day) for 7 days to four adult patients with scalp and body psoriasis. At the end of treatment, the plasma cortisol levels for each of the four patients remained within the normal range and changed little from baseline.
In a study evaluating the effects of mometasone furoate lotion on the [[HPA axis|hypothalamic-pituitary-adrenal (HPA) axis]], 15 mL were applied without occlusion twice daily (30 mL per day) for 7 days to four adult patients with scalp and body psoriasis. At the end of treatment, the plasma [[cortisol]] levels for each of the four patients remained within the normal range and changed little from baseline.


*If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see Prescribing Information for those products.
*If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent [[corticosteroid]]. Recovery of HPA axis function is generally prompt upon discontinuation of topical [[corticosteroids]]. Infrequently, signs and symptoms of [[glucocorticosteroid]] insufficiency may occur requiring supplemental systemic [[corticosteroids]]. For information on systemic supplementation, see Prescribing Information for those products.


*Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (see PRECAUTIONS – PEDIATRIC USE).
*Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios  


*If irritation develops, mometasone furoate topical solution USP, 0.1% should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.
*If irritation develops, mometasone furoate topical solution USP, 0.1% should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with [[corticosteroids]] is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing [[corticosteroids]]. Such an observation should be corroborated with appropriate diagnostic patch testing.
*If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of mometasone furoate topical solution USP, 0.1% should be discontinued until the infection has been adequately controlled.
*If concomitant skin infections are present or develop, an appropriate [[antifungal]] or antibacterial agent should be used. If a favorable response does not occur promptly, use of mometasone furoate topical solution USP, 0.1% should be discontinued until the infection has been adequately controlled.
<!--Adverse Reactions-->
<!--Adverse Reactions-->


<!--Clinical Trials Experience-->
<!--Clinical Trials Experience-->
|clinicalTrials=*In clinical studies involving 209 patients, the incidence of adverse reactions associated with the use of mometasone furoate topical solution USP, 0.1% was 3%. Reported reactions included [[acneiform reaction]], 2; burning, 4; and itching, 1. In an irritation/sensitization study involving 156 normal subjects, the incidence of [[folliculitis]] was 3% (4 subjects).


|clinicalTrials=
*The following adverse reactions were reported to be possibly or probably related to treatment with mometasone furoate topical solution USP, 0.1% during a clinical study, in 14% of 65 pediatric patients 6 months to 2 years of age: decreased [[glucocorticoid]] levels, 4; [[paresthesia]], 2; dry mouth, 1; an unspecified endocrine disorder, 1; [[pruritus]], 1; and an unspecified skin disorder, 1. The following signs of skin atrophy were also observed among 65 patients treated with mometasone furoate topical solution USP, 0.1% in a clinical study: shininess 4, [[telangiectasia]] 2, loss of elasticity 2, and loss of normal skin markings 3. Striae, thinness and bruising were not observed in this study.
 
*In clinical studies involving 209 patients, the incidence of adverse reactions associated with the use of mometasone furoate topical solution USP, 0.1% was 3%. Reported reactions included acneiform reaction, 2; burning, 4; and itching, 1. In an irritation/sensitization study involving 156 normal subjects, the incidence of folliculitis was 3% (4 subjects).


*The following adverse reactions were reported to be possibly or probably related to treatment with mometasone furoate topical solution USP, 0.1% during a clinical study, in 14% of 65 pediatric patients 6 months to 2 years of age: decreased glucocorticoid levels, 4; paresthesia, 2; dry mouth, 1; an unspecified endocrine disorder, 1; pruritus, 1; and an unspecified skin disorder, 1. The following signs of skin atrophy were also observed among 65 patients treated with mometasone furoate topical solution USP, 0.1% in a clinical study: shininess 4, telangiectasia 2, loss of elasticity 2, and loss of normal skin markings 3. Striae, thinness and bruising were not observed in this study.
*The following additional local adverse reactions have been reported infrequently with topical [[corticosteroids]], but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: [[irritation]], dryness, [[hypertrichosis]], [[hypopigmentation]], [[perioral dermatitis]], allergic contact [[dermatitis]], [[secondary infection]], skin [[atrophy]], [[striae]], and [[miliaria]].
 
*The following additional local adverse reactions have been reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: irritation, dryness, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria.


<!--Postmarketing Experience-->
<!--Postmarketing Experience-->
 
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.




<!--Drug Interactions-->
<!--Drug Interactions-->
|drugInteractions=<!--Use in Specific Populations-->
|FDAPregCat=C
|useInPregnancyFDA=* Teratogenic Effect


|drugInteractions=
:*[[Corticosteroids]] have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some [[corticosteroids]] have been shown to be teratogenic after dermal application in laboratory animals.
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* Teratogenic Effects
 
Pregnancy Category C
 
*Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.


*When administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. The doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. Mometasone furoate also caused dystocia and related complications when administered to rats during the end of pregnancy.
:*When administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. The doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. Mometasone furoate also caused [[dystocia]] and related complications when administered to rats during the end of pregnancy.


*In mice, mometasone furoate caused cleft palate at subcutaneous doses of 60 mcg/kg and above. Fetal survival was reduced at 180 mcg/kg. No toxicity was observed at 20 mcg/kg. (Doses of 20, 60 and 180 mcg/kg in the mouse are approximately 0.01, 0.02 and 0.05 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).
:*In mice, mometasone furoate caused cleft palate at subcutaneous doses of 60 mcg/kg and above. Fetal survival was reduced at 180 mcg/kg. No toxicity was observed at 20 mcg/kg. (Doses of 20, 60 and 180 mcg/kg in the mouse are approximately 0.01, 0.02 and 0.05 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).


*In rats, mometasone furoate produced umbilical hernias at topical doses of 600 mcg/kg and above. A dose of 300 mcg/kg produced delays in ossification, but no malformations. (Doses of 300 and 600 mcg/kg in the rat are approximately 0.2 and 0.4 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).
:*In rats, mometasone furoate produced umbilical hernias at topical doses of 600 mcg/kg and above. A dose of 300 mcg/kg produced delays in ossification, but no malformations. (Doses of 300 and 600 mcg/kg in the rat are approximately 0.2 and 0.4 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).


*In rabbits, mometasone furoate caused multiple malformations (e.g., flexed front paws, gallbladder agenesis, umbilical hernia, hydrocephaly) at topical doses of 150 mcg/kg and above (approximately 0.2 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis). In an oral study, mometasone furoate increased resorptions and caused cleft palate and/or head malformations (hydrocephaly and domed head) at 700 mcg/kg. At 2800 mcg/kg most litters were aborted or resorbed. No toxicity was observed at 140 mcg/kg. (Doses of 140, 700 and 2800 mcg/kg in the rabbit are approximately 0.2, 0.9 and 3.6 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).
*In rabbits, mometasone furoate caused multiple malformations (e.g., flexed front paws, gallbladder [[agenesis]], [[umbilical hernia]], [[hydrocephaly]]) at topical doses of 150 mcg/kg and above (approximately 0.2 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis). In an oral study, mometasone furoate increased resorptions and caused cleft palate and/or head malformations ([[hydrocephaly]] and domed head) at 700 mcg/kg. At 2800 mcg/kg most litters were aborted or resorbed. No toxicity was observed at 140 mcg/kg. (Doses of 140, 700 and 2800 mcg/kg in the rabbit are approximately 0.2, 0.9 and 3.6 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).


*When rats received subcutaneous doses of mometasone furoate throughout pregnancy or during the later stages of pregnancy, 15 mcg/kg caused prolonged and difficult labor and reduced the number of live births, birth weight and early pup survival. Similar effects were not observed at 7.5 mcg/kg. (Doses of 7.5 and 15 mcg/kg in the rat are approximately 0.005 and 0.01 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).
*When rats received subcutaneous doses of mometasone furoate throughout pregnancy or during the later stages of pregnancy, 15 mcg/kg caused prolonged and difficult labor and reduced the number of live births, birth weight and early pup survival. Similar effects were not observed at 7.5 mcg/kg. (Doses of 7.5 and 15 mcg/kg in the rat are approximately 0.005 and 0.01 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).


*There are no adequate and well-controlled studies of teratogenic effects from topically applied corticosteroids in pregnant women. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
:*There are no adequate and well-controlled studies of teratogenic effects from topically applied [[corticosteroids]] in pregnant women. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
 
|useInPregnancyAUS=There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInPregnancyAUS=
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInNursing=*Systemically administered [[corticosteroids]] appear in human milk and could suppress growth, interfere with endogenous [[corticosteroid]] production, or cause other untoward effects. It is not known whether topical administration of [[corticosteroids]] could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when mometasone furoate topical solution USP, 0.1% is administered to a nursing woman.
 
|useInPed=*Since safety and efficacy of mometasone furoate topical solution USP, 0.1% have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended.
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
*Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when mometasone furoate topical solution USP, 0.1% is administered to a nursing woman.
|useInPed=
*Since safety and efficacy of mometasone furoate topical solution USP, 0.1% have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended.


*Mometasone furoate topical solution USP, 0.1% caused HPA axis suppression in approximately 29% of pediatric patients ages 6 to 23 months who showed normal adrenal function by Cortrosyn test before starting treatment, and were treated for approximately 3 weeks over a mean body surface area of 40% (range 16% to 90%). The criteria for suppression were: basal cortisol level of ≤5 mcg/dL, 30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4 weeks after stopping treatment, available for 8 of the patients, demonstrated suppressed HPA axis function in one patient, using these same criteria. Long-term use of topical corticosteroids has not been studied in this population. (see CLINICAL PHARMACOLOGY -PHARMACOKINETICS).
*Mometasone furoate topical solution USP, 0.1% caused HPA axis suppression in approximately 29% of pediatric patients ages 6 to 23 months who showed normal adrenal function by Cortrosyn test before starting treatment, and were treated for approximately 3 weeks over a mean body surface area of 40% (range 16% to 90%). The criteria for suppression were: basal cortisol level of ≤5 mcg/dL, 30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4 weeks after stopping treatment, available for 8 of the patients, demonstrated suppressed HPA axis function in one patient, using these same criteria. Long-term use of topical [[corticosteroids]] has not been studied in this population.  


*Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are, therefore, also at greater risk of glucocorticosteroid insufficiency during and/or after withdrawal of treatment. Pediatric patients may be more susceptible than adults to skin atrophy, including striae, when they are treated with topical corticosteroids. Pediatric patients applying topical corticosteroids to greater than 20% of body surface are at higher risk of HPA axis suppression. HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
*Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and [[Cushing's syndrome]] when they are treated with topical [[corticosteroids]]. They are, therefore, also at greater risk of [[glucocorticosteroid insufficiency]] during and/or after withdrawal of treatment. Pediatric patients may be more susceptible than adults to skin atrophy, including striae, when they are treated with topical [[corticosteroids]]. Pediatric patients applying topical [[corticosteroids]] to greater than 20% of body surface are at higher risk of [[HPA axis]] suppression. [[HPA axis]] suppression, [[Cushing's syndrome]], linear growth retardation, delayed weight gain and intracranial [[hypertension]] have been reported in pediatric patients receiving topical [[corticosteroids]]. Manifestations of adrenal suppression in children include low plasma [[cortisol]] levels and absence of response to [[ACTH]] stimulation. Manifestations of [[intracranial hypertension]] include [[bulging fontanelles]], headaches, and bilateral [[papilledema]].
*Mometasone furoate topical solution USP, 0.1% should not be used in the treatment of diaper dermatitis.
*Mometasone furoate topical solution USP, 0.1% should not be used in the treatment of diaper dermatitis.
|useInGeri=
|useInGeri=*Clinical studies of mometasone furoate topical solution USP, 0.1% did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious.
*Clinical studies of mometasone furoate topical solution USP, 0.1% did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInGender=
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with [[renal impairment]].
 
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with [[hepatic impairment]].
|useInRace=
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are [[immunocompromised]].
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
 
|administration=* [[Topical]]
|administration=
|monitoring=*The following tests may be helpful in evaluating patients for HPA axis suppression:
 
* [[Topical]]
|monitoring=
 
*The following tests may be helpful in evaluating patients for HPA axis suppression:
:*ACTH stimulation test
:*ACTH stimulation test
:*A.M. plasma cortisol test
:*A.M. plasma cortisol test
:*Urinary free cortisol test
:*Urinary free cortisol test
<!--IV Compatibility-->
<!--IV Compatibility-->
 
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.


<!--Overdosage-->
<!--Overdosage-->
 
|overdose=*Topically applied mometasone furoate topical solution USP, 0.1% can be absorbed in sufficient amounts to produce systemic effects
|overdose=
*Topically applied mometasone furoate topical solution USP, 0.1% can be absorbed in sufficient amounts to produce systemic effects
<!--Pharmacology-->
<!--Pharmacology-->


<!--Drug box 2-->
<!--Drug box 2-->
|drugBox={{Drugbox2
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457636529
| IUPAC_name = (11β,16α)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate
| image = Mometasone furoate.png
| image2 = Mometasone furoate ball-and-stick.png
<!--Clinical data-->
| tradename =  Elocon Elocom, Elomet, Elosalic  Novasone  Nasonex Asmanex Twisthaler  Essex pharma markets the medication under the brand name Ecural mometAid.
| Drugs.com = {{drugs.com|monograph|mometasone_furoate}}
| pregnancy_US = C
| legal_status = Rx Only (US)
| routes_of_administration = topical, inhalation


|drugBox=
<!--Pharmacokinetic data-->
| bioavailability = Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to [[fluticasone]].<ref>{{cite journal | title = Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate | author = Zia R Tayab, Tom C Fardon, Daniel K C Lee, Kay Haggart, Lesley C McFarlane, Brian J Lipworth, and Günther Hochhaus | journal = Br J Clin Pharmacol |date=November 2007 | volume = 64 | issue = 5 | pages = 698–705 | doi = 10.1111/j.1365-2125.2007.02919.x | pmid = 17509041 | pmc = 2203259}}</ref>
| protein_bound = 98% to 99%
| metabolism = [[hepatic]]
| elimination_half-life = 5.8 hours


<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 105102-22-5
| CAS_supplemental = {{CAS|83919-23-7}}
| ATC_prefix = D07
| ATC_suffix = AC13
| ATC_supplemental = {{ATC|R01|AD09}}, {{ATC|R03|BA07}}
| PubChem = 441336
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00764
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 390091
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 47564
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1161


<!--Chemical data-->
| chemical_formula = C<sub>22</sub>H<sub>28</sub>Cl<sub>2</sub>O<sub>4</sub> for Mometasone<br/> C<sub>27</sub>H<sub>30</sub>O<sub>6</sub>Cl<sub>2</sub> as Furoate


<!--Mechanism of Action-->
| molecular_weight = 427.361 g/mol (Mometasone) <br/> 521.4 g/mol (Furoate)
| smiles = O=C(O[C@]2(C(=O)CCl)[C@H](C)C[C@H]3[C@@H]4CCC\1=C\C(=O)\C=C/[C@]/1(C)[C@@]4(Cl)[C@@H](O)C[C@]23C)c5occc5
| InChI = 1/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
| InChIKey = WOFMFGQZHJDGCX-ZULDAHANBU
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WOFMFGQZHJDGCX-ZULDAHANSA-N
| synonyms = <small>(9''R'',10''S'',11''S'',13''S'',14''S'',16''R'',17''R'')-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3''H''-cyclopenta[''a'']phenanthren-17-yl furan-2-carboxylate</small>
}}


|mechAction=


* Like other topical corticosteroids, mometasone furoate has anti-inflammatory, anti-pruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
 
<!--Mechanism of Action-->
|mechAction=* Like other topical [[corticosteroids]], mometasone furoate has [[anti-inflammatory]], [[anti-pruritic]], and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical [[steroids]], in general, is unclear. However, [[corticosteroids]] are thought to act by the induction of [[phospholipase]] A2inhibitory proteins, collectively called [[lipocortins]]. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as [[prostaglandins]] and [[leukotrienes]] by inhibiting the release of their common precursor [[arachidonic acid]]. [[Arachidonic acid]] is released from membrane [[phospholipids]] by [[phospholipase A2]].


<!--Structure-->
<!--Structure-->
 
|structure=* Mometasone furoate topical solution USP, 0.1%, contains mometasone furoate, USP for dermatologic use. Mometasone furoate is a synthetic [[corticosteroid]] with anti-inflammatory activity.
|structure=
 
* Mometasone furoate topical solution USP, 0.1%, contains mometasone furoate, USP for dermatologic use. Mometasone furoate is a synthetic corticosteroid with anti-inflammatory activity.
*Chemically, mometasone furoate is 9α,21-dichloro-llβ,17-dihydroxy-16α -methylpregna-l,4-diene-3,20-dione 17-(2-furoate), with the empirical formula C27H30Cl2O6, a molecular weight of 521.4 and the following structural formula:
*Chemically, mometasone furoate is 9α,21-dichloro-llβ,17-dihydroxy-16α -methylpregna-l,4-diene-3,20-dione 17-(2-furoate), with the empirical formula C27H30Cl2O6, a molecular weight of 521.4 and the following structural formula:


Line 253: Line 191:
*Each gram of mometasone furoate topical solution USP, 0.1% contains: 1 mg mometasone furoate, USP in a base of isopropyl alcohol, USP (40%); hexylene glycol, NF; hydroxypropyl cellulose, NF; sodium phosphate monobasic anhydrous, USP; purified water, USP; glycerin, USP; oleic acid, NF; may also contain phosphoric acid NF to adjust the pH to approximately 4.5.
*Each gram of mometasone furoate topical solution USP, 0.1% contains: 1 mg mometasone furoate, USP in a base of isopropyl alcohol, USP (40%); hexylene glycol, NF; hydroxypropyl cellulose, NF; sodium phosphate monobasic anhydrous, USP; purified water, USP; glycerin, USP; oleic acid, NF; may also contain phosphoric acid NF to adjust the pH to approximately 4.5.
<!--Pharmacodynamics-->
<!--Pharmacodynamics-->
 
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.


<!--Pharmacokinetics-->
<!--Pharmacokinetics-->
|PK=*The extent of percutaneous absorption of topical [[corticosteroids]] is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with [[hydrocortisone]] for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of [[hydrocortisone]] for 96 hours markedly enhances penetration. Studies in humans indicate that approximately 0.7% of the applied dose of mometasone furoate ointment USP, 0.1%, enters the circulation after 8 hours of contact on normal skin without occlusion. A similar minimal degree of absorption of the [[corticosteroid]] from the solution formulation would be anticipated. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.


|PK=
*Studies performed with mometasone furoate topical solution USP, 0.1% indicate that it is in the medium range of potency as compared with other topical [[corticosteroids]].
 
*The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Studies in humans indicate that approximately 0.7% of the applied dose of mometasone furoate ointment USP, 0.1%, enters the circulation after 8 hours of contact on normal skin without occlusion. A similar minimal degree of absorption of the corticosteroid from the solution formulation would be anticipated. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
 
*Studies performed with mometasone furoate topical solution USP, 0.1% indicate that it is in the medium range of potency as compared with other topical corticosteroids.


*In a study evaluating the effects of mometasone furoate lotion on the hypothalamic-pituitary-adrenal (HPA) axis, 15 mL were applied without occlusion twice daily (30 mL per day) for 7 days to 4 adult patients with scalp and body psoriasis. At the end of treatment, the plasma cortisol levels for each of the 4 patients remained within the normal range and changed little from baseline.
*In a study evaluating the effects of mometasone furoate lotion on the hypothalamic-pituitary-adrenal (HPA) axis, 15 mL were applied without occlusion twice daily (30 mL per day) for 7 days to 4 adult patients with scalp and body psoriasis. At the end of treatment, the plasma cortisol levels for each of the 4 patients remained within the normal range and changed little from baseline.


*Sixty-five pediatric patients ages 6 to 23 months, with atopic dermatitis, were enrolled in an open-label, hypothalamic-pituitary-adrenal (HPA) axis safety study. Mometasone furoate topical solution USP, 0.1% was applied once daily for approximately 3 weeks over a mean body surface area of 40% (range 16% to 90%). In approximately 29% of patients who showed normal adrenal function by Cortrosyn test before starting treatment, adrenal suppression was observed at the end of treatment with mometasone furoate topical solution USP, 0.1%. The criteria for suppression were: basal cortisol level of ≤5 mcg/dL, 30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4 weeks after stopping treatment, available for 8 of the patients, demonstrated suppressed HPA axis function in one patient, using these same criteria.
*Sixty-five pediatric patients ages 6 to 23 months, with [[atopic dermatitis]], were enrolled in an open-label, hypothalamic-pituitary-adrenal (HPA) axis safety study. Mometasone furoate topical solution USP, 0.1% was applied once daily for approximately 3 weeks over a mean body surface area of 40% (range 16% to 90%). In approximately 29% of patients who showed normal adrenal function by [[Cortrosyn]] test before starting treatment, adrenal suppression was observed at the end of treatment with mometasone furoate topical solution USP, 0.1%. The criteria for suppression were: basal [[cortisol]] level of ≤5 mcg/dL, 30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4 weeks after stopping treatment, available for 8 of the patients, demonstrated suppressed [[HPA axis]] function in one patient, using these same criteria.
<!--Nonclinical Toxicology-->
<!--Nonclinical Toxicology-->
 
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.


<!--Clinical Studies-->
<!--Clinical Studies-->
 
|clinicalStudies=*Carcinogenesis, Mutagenesis, Impairment of Fertility
|clinicalStudies=
 
*Carcinogenesis, Mutagenesis, Impairment of Fertility
:*Long-term animal studies have not been performed to evaluate the carcinogenic potential of mometasone furoate topical solution USP, 0.1%. Long-term carcinogenicity studies of mometasone furoate were conducted by the inhalation route in rats and mice. In a 2-year carcinogenicity study in Sprague-Dawley rats, mometasone furoate demonstrated no statistically significant increase of tumors at inhalation doses up to 67 mcg/kg (approximately 0.04 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis). In a 19-month carcinogenicity study in Swiss CD-1 mice, mometasone furoate demonstrated no statistically significant increase in the incidence of tumors at inhalation doses up to 160 mcg/kg (approximately 0.05 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).
:*Long-term animal studies have not been performed to evaluate the carcinogenic potential of mometasone furoate topical solution USP, 0.1%. Long-term carcinogenicity studies of mometasone furoate were conducted by the inhalation route in rats and mice. In a 2-year carcinogenicity study in Sprague-Dawley rats, mometasone furoate demonstrated no statistically significant increase of tumors at inhalation doses up to 67 mcg/kg (approximately 0.04 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis). In a 19-month carcinogenicity study in Swiss CD-1 mice, mometasone furoate demonstrated no statistically significant increase in the incidence of tumors at inhalation doses up to 160 mcg/kg (approximately 0.05 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).


:*Mometasone furoate increased chromosomal aberrations in an in vitro Chinese hamster ovary cell assay, but did not increase chromosomal aberrations in an in vitro Chinese hamster lung cell assay. Mometasone furoate was not mutagenic in the Ames test or mouse lymphoma assay, and was not clastogenic in an in vivo mouse micronucleus assay, a rat bone marrow chromosomal aberration assay, or a mouse male germ-cell chromosomal aberration assay. Mometasone furoate also did not induce unscheduled DNA synthesis in vivo in rat hepatocytes.
:*Mometasone furoate increased chromosomal aberrations in an in vitro Chinese hamster ovary cell assay, but did not increase chromosomal aberrations in an in vitro Chinese hamster lung cell assay. Mometasone furoate was not mutagenic in the Ames test or mouse lymphoma assay, and was not clastogenic in an in vivo mouse [[micronucleus assay]], a rat bone marrow chromosomal aberration assay, or a mouse male germ-cell chromosomal aberration assay. Mometasone furoate also did not induce unscheduled DNA synthesis in vivo in rat hepatocytes.


:*In reproductive studies in rats, impairment of fertility was not produced in male or female rats by subcutaneous doses up to 15 mcg/kg (approximately 0.01 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).
:*In reproductive studies in rats, impairment of [[fertility]] was not produced in male or female rats by subcutaneous doses up to 15 mcg/kg (approximately 0.01 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).


(-How Supplied-->
(-How Supplied-->
 
|howSupplied=* Mometasone furoate topical solution USP, 0.1%, is supplied in 30-mL (27.5 g) (NDC 45802-118-59) and 60-mL (55 g) (NDC 45802-118-46) bottles; boxes of one.
|howSupplied=
 
* Mometasone furoate topical solution USP, 0.1%, is supplied in 30-mL (27.5 g) (NDC 45802-118-59) and 60-mL (55 g) (NDC 45802-118-46) bottles; boxes of one.
*Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].
*Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].
<!--Patient Counseling Information-->
<!--Patient Counseling Information-->
 
|fdaPatientInfo=*Patients using topical [[corticosteroids]] should receive the following information and instructions.
|fdaPatientInfo=
 
*Patients using topical corticosteroids should receive the following information and instructions.
*This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
*This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
*This medication should not be used for any disorder other than that for which it was prescribed.
*This medication should not be used for any disorder other than that for which it was prescribed.
Line 303: Line 223:
*Parents of pediatric patients should be advised not to use mometasone furoate topical solution USP, 0.1% in the treatment of diaper dermatitis. Mometasone furoate topical solution USP, 0.1% should not be applied in the diaper area, as diapers or plastic pants may constitute occlusive dressing  
*Parents of pediatric patients should be advised not to use mometasone furoate topical solution USP, 0.1% in the treatment of diaper dermatitis. Mometasone furoate topical solution USP, 0.1% should not be applied in the diaper area, as diapers or plastic pants may constitute occlusive dressing  
*This medication should not be used on the face, underarms, or groin areas unless directed by the physician.
*This medication should not be used on the face, underarms, or groin areas unless directed by the physician.
*As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician.
*As with other [[corticosteroids]], therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician.
*Other corticosteroid-containing products should not be used with mometasone furoate topical solution USP, 0.1% without first consulting with the physician.
*Other [[corticosteroid]]-containing products should not be used with mometasone furoate topical solution USP, 0.1% without first consulting with the physician.
<!--Precautions with Alcohol-->
<!--Precautions with Alcohol-->
 
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=
 
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


<!--Brand Names-->
<!--Brand Names-->
|brandNames=
|brandNames=
*


<!--Look-Alike Drug Names-->
<!--Look-Alike Drug Names-->
|lookAlike=
|lookAlike=
*


<!--Drug Shortage Status-->
<!--Drug Shortage Status-->
|drugShortage=
|drugShortage=
}}
}}
<!--Pill Image-->
<!--Pill Image-->


Latest revision as of 16:45, 20 August 2015

Mometasone (topical)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Mometasone (topical) is an anti-inflammatory that is FDA approved for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Common adverse reactions include abdominal pain, candidiasis, indigestion, nausea, backache, musculoskeletal pain, myalgia, headache, dysmenorrhea, allergic rhinitis, epistaxis, pharyngitis, upper respiratory infection..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Mometasone furoate topical solution USP, 0.1%, is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Since safety and efficacy of mometasone furoate topical solution USP, 0.1% have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended.

Dosage

  • Apply a few drops of mometasone furoate topical solution USP, 0.1% to the affected skin areas once daily and massage lightly until it disappears. For the most effective and economical use, hold the nozzle of the bottle very close to the affected areas and gently squeeze. Since safety and efficacy of mometasone furoate topical solution USP, 0.1% have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended.
  • As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
  • Mometasone furoate topical solution USP, 0.1% should not be used with occlusive dressings unless directed by a physician. Mometasone furoate topical solution USP, 0.1% should not be applied in the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Mometasone (topical) in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Mometasone (topical) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Mometasone (topical) in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Mometasone (topical) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Mometasone (topical) in pediatric patients.

Contraindications

  • Mometasone furoate topical solution USP, 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.

Warnings

Precautions

In a study evaluating the effects of mometasone furoate lotion on the hypothalamic-pituitary-adrenal (HPA) axis, 15 mL were applied without occlusion twice daily (30 mL per day) for 7 days to four adult patients with scalp and body psoriasis. At the end of treatment, the plasma cortisol levels for each of the four patients remained within the normal range and changed little from baseline.

  • If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see Prescribing Information for those products.
  • Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios
  • If irritation develops, mometasone furoate topical solution USP, 0.1% should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.
  • If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of mometasone furoate topical solution USP, 0.1% should be discontinued until the infection has been adequately controlled.

Adverse Reactions

Clinical Trials Experience

  • In clinical studies involving 209 patients, the incidence of adverse reactions associated with the use of mometasone furoate topical solution USP, 0.1% was 3%. Reported reactions included acneiform reaction, 2; burning, 4; and itching, 1. In an irritation/sensitization study involving 156 normal subjects, the incidence of folliculitis was 3% (4 subjects).
  • The following adverse reactions were reported to be possibly or probably related to treatment with mometasone furoate topical solution USP, 0.1% during a clinical study, in 14% of 65 pediatric patients 6 months to 2 years of age: decreased glucocorticoid levels, 4; paresthesia, 2; dry mouth, 1; an unspecified endocrine disorder, 1; pruritus, 1; and an unspecified skin disorder, 1. The following signs of skin atrophy were also observed among 65 patients treated with mometasone furoate topical solution USP, 0.1% in a clinical study: shininess 4, telangiectasia 2, loss of elasticity 2, and loss of normal skin markings 3. Striae, thinness and bruising were not observed in this study.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Mometasone (topical) in the drug label.

Drug Interactions

There is limited information regarding Mometasone (topical) Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C

  • Teratogenic Effect
  • Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.
  • When administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. The doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. Mometasone furoate also caused dystocia and related complications when administered to rats during the end of pregnancy.
  • In mice, mometasone furoate caused cleft palate at subcutaneous doses of 60 mcg/kg and above. Fetal survival was reduced at 180 mcg/kg. No toxicity was observed at 20 mcg/kg. (Doses of 20, 60 and 180 mcg/kg in the mouse are approximately 0.01, 0.02 and 0.05 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).
  • In rats, mometasone furoate produced umbilical hernias at topical doses of 600 mcg/kg and above. A dose of 300 mcg/kg produced delays in ossification, but no malformations. (Doses of 300 and 600 mcg/kg in the rat are approximately 0.2 and 0.4 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).
  • In rabbits, mometasone furoate caused multiple malformations (e.g., flexed front paws, gallbladder agenesis, umbilical hernia, hydrocephaly) at topical doses of 150 mcg/kg and above (approximately 0.2 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis). In an oral study, mometasone furoate increased resorptions and caused cleft palate and/or head malformations (hydrocephaly and domed head) at 700 mcg/kg. At 2800 mcg/kg most litters were aborted or resorbed. No toxicity was observed at 140 mcg/kg. (Doses of 140, 700 and 2800 mcg/kg in the rabbit are approximately 0.2, 0.9 and 3.6 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).
  • When rats received subcutaneous doses of mometasone furoate throughout pregnancy or during the later stages of pregnancy, 15 mcg/kg caused prolonged and difficult labor and reduced the number of live births, birth weight and early pup survival. Similar effects were not observed at 7.5 mcg/kg. (Doses of 7.5 and 15 mcg/kg in the rat are approximately 0.005 and 0.01 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).
  • There are no adequate and well-controlled studies of teratogenic effects from topically applied corticosteroids in pregnant women. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.


Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Mometasone (topical) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Mometasone (topical) during labor and delivery.

Nursing Mothers

  • Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when mometasone furoate topical solution USP, 0.1% is administered to a nursing woman.

Pediatric Use

  • Since safety and efficacy of mometasone furoate topical solution USP, 0.1% have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended.
  • Mometasone furoate topical solution USP, 0.1% caused HPA axis suppression in approximately 29% of pediatric patients ages 6 to 23 months who showed normal adrenal function by Cortrosyn test before starting treatment, and were treated for approximately 3 weeks over a mean body surface area of 40% (range 16% to 90%). The criteria for suppression were: basal cortisol level of ≤5 mcg/dL, 30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4 weeks after stopping treatment, available for 8 of the patients, demonstrated suppressed HPA axis function in one patient, using these same criteria. Long-term use of topical corticosteroids has not been studied in this population.
  • Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are, therefore, also at greater risk of glucocorticosteroid insufficiency during and/or after withdrawal of treatment. Pediatric patients may be more susceptible than adults to skin atrophy, including striae, when they are treated with topical corticosteroids. Pediatric patients applying topical corticosteroids to greater than 20% of body surface are at higher risk of HPA axis suppression. HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
  • Mometasone furoate topical solution USP, 0.1% should not be used in the treatment of diaper dermatitis.

Geriatic Use

  • Clinical studies of mometasone furoate topical solution USP, 0.1% did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious.

Gender

There is no FDA guidance on the use of Mometasone (topical) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Mometasone (topical) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Mometasone (topical) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Mometasone (topical) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Mometasone (topical) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Mometasone (topical) in patients who are immunocompromised.

Administration and Monitoring

Administration

Monitoring

  • The following tests may be helpful in evaluating patients for HPA axis suppression:
  • ACTH stimulation test
  • A.M. plasma cortisol test
  • Urinary free cortisol test

IV Compatibility

There is limited information regarding IV Compatibility of Mometasone (topical) in the drug label.

Overdosage

  • Topically applied mometasone furoate topical solution USP, 0.1% can be absorbed in sufficient amounts to produce systemic effects

Pharmacology

Template:Px
Template:Px
Mometasone (topical)
Systematic (IUPAC) name
(11β,16α)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate
Identifiers
CAS number 105102-22-5
83919-23-7
ATC code D07AC13 R01AD09 (WHO), R03BA07 (WHO)
PubChem 441336
DrugBank DB00764
Chemical data
Formula C22H28Cl2O4 for Mometasone
C27H30O6Cl2 as Furoate
Mol. mass 427.361 g/mol (Mometasone)
521.4 g/mol (Furoate)
SMILES eMolecules & PubChem
Synonyms (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
Pharmacokinetic data
Bioavailability Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to fluticasone.[1]
Protein binding 98% to 99%
Metabolism hepatic
Half life 5.8 hours
Excretion ?
Therapeutic considerations
Pregnancy cat.

C(US)

Legal status

Rx Only (US)

Routes topical, inhalation

Mechanism of Action

Structure

  • Mometasone furoate topical solution USP, 0.1%, contains mometasone furoate, USP for dermatologic use. Mometasone furoate is a synthetic corticosteroid with anti-inflammatory activity.
  • Chemically, mometasone furoate is 9α,21-dichloro-llβ,17-dihydroxy-16α -methylpregna-l,4-diene-3,20-dione 17-(2-furoate), with the empirical formula C27H30Cl2O6, a molecular weight of 521.4 and the following structural formula:
This image is provided by the National Library of Medicine.
  • Mometasone furoate is a white to off-white powder insoluble in water, freely soluble in acetone and in methylene chloride and sparingly soluble in heptane.
  • Each gram of mometasone furoate topical solution USP, 0.1% contains: 1 mg mometasone furoate, USP in a base of isopropyl alcohol, USP (40%); hexylene glycol, NF; hydroxypropyl cellulose, NF; sodium phosphate monobasic anhydrous, USP; purified water, USP; glycerin, USP; oleic acid, NF; may also contain phosphoric acid NF to adjust the pH to approximately 4.5.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Mometasone (topical) in the drug label.

Pharmacokinetics

  • The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Studies in humans indicate that approximately 0.7% of the applied dose of mometasone furoate ointment USP, 0.1%, enters the circulation after 8 hours of contact on normal skin without occlusion. A similar minimal degree of absorption of the corticosteroid from the solution formulation would be anticipated. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
  • Studies performed with mometasone furoate topical solution USP, 0.1% indicate that it is in the medium range of potency as compared with other topical corticosteroids.
  • In a study evaluating the effects of mometasone furoate lotion on the hypothalamic-pituitary-adrenal (HPA) axis, 15 mL were applied without occlusion twice daily (30 mL per day) for 7 days to 4 adult patients with scalp and body psoriasis. At the end of treatment, the plasma cortisol levels for each of the 4 patients remained within the normal range and changed little from baseline.
  • Sixty-five pediatric patients ages 6 to 23 months, with atopic dermatitis, were enrolled in an open-label, hypothalamic-pituitary-adrenal (HPA) axis safety study. Mometasone furoate topical solution USP, 0.1% was applied once daily for approximately 3 weeks over a mean body surface area of 40% (range 16% to 90%). In approximately 29% of patients who showed normal adrenal function by Cortrosyn test before starting treatment, adrenal suppression was observed at the end of treatment with mometasone furoate topical solution USP, 0.1%. The criteria for suppression were: basal cortisol level of ≤5 mcg/dL, 30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4 weeks after stopping treatment, available for 8 of the patients, demonstrated suppressed HPA axis function in one patient, using these same criteria.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Mometasone (topical) in the drug label.

Clinical Studies

  • Carcinogenesis, Mutagenesis, Impairment of Fertility
  • Long-term animal studies have not been performed to evaluate the carcinogenic potential of mometasone furoate topical solution USP, 0.1%. Long-term carcinogenicity studies of mometasone furoate were conducted by the inhalation route in rats and mice. In a 2-year carcinogenicity study in Sprague-Dawley rats, mometasone furoate demonstrated no statistically significant increase of tumors at inhalation doses up to 67 mcg/kg (approximately 0.04 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis). In a 19-month carcinogenicity study in Swiss CD-1 mice, mometasone furoate demonstrated no statistically significant increase in the incidence of tumors at inhalation doses up to 160 mcg/kg (approximately 0.05 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).
  • Mometasone furoate increased chromosomal aberrations in an in vitro Chinese hamster ovary cell assay, but did not increase chromosomal aberrations in an in vitro Chinese hamster lung cell assay. Mometasone furoate was not mutagenic in the Ames test or mouse lymphoma assay, and was not clastogenic in an in vivo mouse micronucleus assay, a rat bone marrow chromosomal aberration assay, or a mouse male germ-cell chromosomal aberration assay. Mometasone furoate also did not induce unscheduled DNA synthesis in vivo in rat hepatocytes.
  • In reproductive studies in rats, impairment of fertility was not produced in male or female rats by subcutaneous doses up to 15 mcg/kg (approximately 0.01 times the estimated maximum clinical topical dose from mometasone furoate topical solution USP, 0.1% on a mcg/m2 basis).

(-How Supplied-->

How Supplied

  • Mometasone furoate topical solution USP, 0.1%, is supplied in 30-mL (27.5 g) (NDC 45802-118-59) and 60-mL (55 g) (NDC 45802-118-46) bottles; boxes of one.
  • Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

Storage

There is limited information regarding Mometasone (topical) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Mometasone (topical) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Mometasone (topical) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

  • Patients using topical corticosteroids should receive the following information and instructions.
  • This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
  • This medication should not be used for any disorder other than that for which it was prescribed.
  • The treated skin area should not be bandaged or otherwise covered or wrapped so as to be occlusive unless directed by the physician.
  • Patients should report to their physician any signs of local adverse reactions.
  • Parents of pediatric patients should be advised not to use mometasone furoate topical solution USP, 0.1% in the treatment of diaper dermatitis. Mometasone furoate topical solution USP, 0.1% should not be applied in the diaper area, as diapers or plastic pants may constitute occlusive dressing
  • This medication should not be used on the face, underarms, or groin areas unless directed by the physician.
  • As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician.
  • Other corticosteroid-containing products should not be used with mometasone furoate topical solution USP, 0.1% without first consulting with the physician.

Precautions with Alcohol

  • Alcohol-Mometasone (topical) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Mometasone (topical) Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Mometasone (topical) Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Zia R Tayab, Tom C Fardon, Daniel K C Lee, Kay Haggart, Lesley C McFarlane, Brian J Lipworth, and Günther Hochhaus (November 2007). "Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate". Br J Clin Pharmacol. 64 (5): 698–705. doi:10.1111/j.1365-2125.2007.02919.x. PMC 2203259. PMID 17509041.



{{#subobject: 

 |Label Page=Mometasone (topical)
 |Label Name=Mometasone (topical)02.png

}}


{{#subobject: 

 |Label Page=Mometasone (topical)
 |Label Name=Mometasone (topical)03.png

}}

{{#subobject: 

 |Label Page=Mometasone (topical)
 |Label Name=Mometasone (topical)04.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Mometasone_(topical)&oldid=1137083"